Baseline cardiac comorbidities and cardiotoxicity after treatment based on R-CHOP and R-COMP
| Comorbidities (n = 691) . | Grade . | R-CHOP . | R-COMP . | Total . | P value . |
|---|---|---|---|---|---|
| . | n (%) . | n (%) . | n (%) . | ||
| Heart CIRS-G | 0-1 | 351 (92) | 209 (68) | 560 (81) | < .001 |
| 2-4 | 32 (8) | 99 (32) | 131 (19) | ||
| Total | 383 | 308 | 691 | ||
| Cardiopathy with CIRS-G 2/4 | R-CHOP | R-COMP | Total | ||
| Ischemic cardiopathy | 5 (19) | 28 (33) | 33 (30) | .225 | |
| Atrial fibrillation | 8 (30) | 31 (37) | 39 (35) | .644 | |
| Hypertension | 3 (11) | 4 (5) | 7 (6) | .358 | |
| Ventricular hypertrophy | 2 (7) | 4 (5) | 6 (5) | .632 | |
| Valvulopathy | 7 (26) | 5 (6) | 12 (11) | .008 | |
| Arrhythmia | 2 (7) | 2 (2) | 4 (4) | .248 | |
| LVEF <50% | — | 3 (4) | 3 (3) | ||
| Other | — | 7 (8) | 7 (6) | ||
| Missing | 6 | 14 | 20 | ||
| CTCAE treatment (n = 175) | Grade | R-CHOP | R-COMP | Total | P value |
| 0 | 55 (86) | 97 (87) | 152 (87) | .484 | |
| 1 | 1 (2) | 5 (4) | 6 (3) | ||
| 2 | 6 (9) | 5 (4) | 11 (6) | ||
| 3-4 | 2 (3) | 4 (4) | 6 (3) | ||
| Total | 64 | 111 | 175 | ||
| Any vs 0 | 9 (14) | 14 (13) | 23 (13) | .819 | |
| 3-4 vs 0-2 | 2 (3) | 4 (4) | 6 (3) | 1.000 |
| Comorbidities (n = 691) . | Grade . | R-CHOP . | R-COMP . | Total . | P value . |
|---|---|---|---|---|---|
| . | n (%) . | n (%) . | n (%) . | ||
| Heart CIRS-G | 0-1 | 351 (92) | 209 (68) | 560 (81) | < .001 |
| 2-4 | 32 (8) | 99 (32) | 131 (19) | ||
| Total | 383 | 308 | 691 | ||
| Cardiopathy with CIRS-G 2/4 | R-CHOP | R-COMP | Total | ||
| Ischemic cardiopathy | 5 (19) | 28 (33) | 33 (30) | .225 | |
| Atrial fibrillation | 8 (30) | 31 (37) | 39 (35) | .644 | |
| Hypertension | 3 (11) | 4 (5) | 7 (6) | .358 | |
| Ventricular hypertrophy | 2 (7) | 4 (5) | 6 (5) | .632 | |
| Valvulopathy | 7 (26) | 5 (6) | 12 (11) | .008 | |
| Arrhythmia | 2 (7) | 2 (2) | 4 (4) | .248 | |
| LVEF <50% | — | 3 (4) | 3 (3) | ||
| Other | — | 7 (8) | 7 (6) | ||
| Missing | 6 | 14 | 20 | ||
| CTCAE treatment (n = 175) | Grade | R-CHOP | R-COMP | Total | P value |
| 0 | 55 (86) | 97 (87) | 152 (87) | .484 | |
| 1 | 1 (2) | 5 (4) | 6 (3) | ||
| 2 | 6 (9) | 5 (4) | 11 (6) | ||
| 3-4 | 2 (3) | 4 (4) | 6 (3) | ||
| Total | 64 | 111 | 175 | ||
| Any vs 0 | 9 (14) | 14 (13) | 23 (13) | .819 | |
| 3-4 vs 0-2 | 2 (3) | 4 (4) | 6 (3) | 1.000 |
Fisher exact test. Type of cardiopathy with CIRS 2 or 4 in 111 cases out of 131 (85%).
CTCAE, common terminology criteria for adverse events.